Company Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States.
The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.
It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts.
The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications.
Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
| Country | United States |
| IPO Date | Jun 15, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Dr. Jayson M. Rieger M.B.A., Ph.D. |
Contact Details
Address: 44 West Gay Street West Chester, Pennsylvania United States | |
| Website | https://www.verrica.com |
Stock Details
| Ticker Symbol | VRCA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001660334 |
| CUSIP Number | 92511W108 |
| ISIN Number | US92511W1080 |
| Employer ID | 46-3137900 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jayson M. Rieger M.B.A., Ph.D. | President, Chief Executive Officer & Director |
| Christopher G. Hayes | Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel |
| John J. Kirby CPA | Interim Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 09, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Dec 09, 2024 | 4 | Filing |
| Dec 09, 2024 | 3 | Filing |
| Dec 09, 2024 | S-8 | Filing |
| Dec 09, 2024 | 8-K | Current Report |
| Nov 26, 2024 | SC 13D/A | [Amend] Filing |
| Nov 26, 2024 | 4 | Filing |
| Nov 26, 2024 | 4 | Filing |
| Nov 26, 2024 | 4 | Filing |
| Nov 21, 2024 | 8-K | Current Report |